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A
 
BSTRACT
 
Long-acting 
 
β
 
2
 
-adrenergic receptor agonists (LABA),
a class of agents for the long-term management of
childhood bronchial asthma, are recommended for
use in combination with steroid inhalation for the treat-
ment of the morning dip in severe childhood asthma.
In the present review, salmeterol (SM), a LABA inhalant
with a long-acting bronchodilator effect, was com-
pared with the recently introduced tulobuterol patch
(TBP) in terms of safety and efficacy, based on their
respective clinical effects on childhood asthma. From a
clinical perspective, both drugs had a preventive effect
by suppressing the morning dip and exercise-induced
asthma when used concomitantly with an inhaled
corticosteroid, and both agents were associated with a
lower incidence of adverse effects on the cardio-
vascular system than oral 
 
β
 
2
 
-adrenergic receptor ago-
nists. Based on these findings, both SM and TBP are
concluded to be highly efficacious and safe broncho-
dilator agents that are appropriate for the long-term
management of childhood asthma.
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I
 
NTRODUCTION
 
Bronchial asthma is defined as a reversible bronchial
occlusive disease and agents with potent bronchodilator
effects, such as 
 
β
 
2
 
-adrenergic receptor agonists, have
long been used as first-choice agents for asthma attacks.
In recent years, the pathology of bronchial asthma has
come to be recognized as eosinophil-mediated chronic
inflammation of the airways and the clinical value of
various anti-inflammatory agents, such as inhaled corti-
costeroids, has been emphasized,
 
1
 
 even in children.
Therefore, the place of 
 
β
 
2
 
-adrenergic receptor agonists
as therapeutic agents has been reviewed and short-
acting 
 
β
 
2
 
-adrenergic receptor agonists (SABA) are pre-
ferred as relievers, whereas long-acting 
 
β
 
2
 
-adrenergic
receptor agonists (LABA) are recommended as controllers
(Fig. 1). Salmeterol (SM) is an LABA and the tulobuterol
patch (TBP), a recently developed 
 
β
 
2
 
-adrenergic receptor
agonist transdermal absorption system, is a drug delivery
system (DDS) that provides long-acting and effective
bronchodilation. In the present paper, we review the role
of these agents as controllers in the treatment of
childhood asthma.
 
L
 
ONG
 
-
 
ACTING
 
 
 
β
 
2
 
-
 
ADRENERGIC
 
 
 
RECEPTOR
 
 
 
AGONISTS
 
Of the many formulations of 
 
β
 
2
 
-adrenergic receptor
agonists available, oral preparations, inhalants, quanti-
tative inhalation-type aerosols (aerosol, metered dose
inhalers) and patch compounds are currently used. 
 
β
 
2
 
-
Adrenergic receptor agonists are classified according to
their 
 
β
 
2
 
-adrenergic receptor selectivity, duration of effec-
tiveness and formulation (Table 1). The SABA have been
used to treat acute attacks (relievers) and the oral drugs
procaterol, clenbuterol and formoterol have recently
been classified as controllers. In recent years LABA, such
as salmeterol or TBP, have been shown to have high
efficacy in the treatment of severe asthma when com-
bined with anti-inflammatory agents, such as inhaled
corticosteroids (Fig. 1).
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Salmeterol
 
Special features of salmeterol
 
The selectivity of salmeterol for the 
 
β
 
2
 
-adrenergic recep-
tors of airway smooth muscle is approximately 85 000-
fold its selectivity for the 
 
β
 
1
 
-adrenergic receptors of the
heart, indicating very high 
 
β
 
2
 
-adrenergic receptor selec-
tivity of the drug.
 
2
 
 Salmeterol manifests efficacy within
15–17 min after inhalation. Although it is slightly slower
acting than salbutamol, its duration of action is more
than 12 h, implying that two doses a day are sufficient.
 
Suppressive effect of salmeterol on the morning dip
 
In a randomized double-blind trial of 207 asthmatic
patients ranging in age from 4 to 11 years, changes in
forced expiratory volume in 1 s (FEV
 
1.0
 
) were compared
during 12 weeks of treatment with salmeterol (50 
 
µ
 
g)
and a placebo inhalant. The FEV
 
1.0
 
 increased signifi-
cantly with improvement in lung function for 12 h on day
1 in the group treated with salmeterol compared with
controls and a similar tendency was observed even after
the 12 week regimen.
 
3
 
Fig. 1
 
Rank of long-acting
 
β
 
2
 
-adrenergic receptor agonists
as agents for the treatment of
pediatric bronchial asthma.
DSCG, disodium cromoglycate;
MDI, metered dose inhaler.
 
Table 1
 
Types and special features of 
 
β
 
2
 
-adrenergic receptor agonists
Generic name Selectivity Duration of 
(adrenergic receptors)
Formulation action (h)
First generation
Epinephrine
 
α
 
1
 
, 
 
β
 
1
 
, 
 
β
 
2
 
< 1 Injection, inhalant
Isoproterenol
 
α
 
1
 
, 
 
β
 
1
 
 = β
 
2
 
< 1 Injection, inhalant
Second generation
Salbutamol
 
β
 
1
 
 
 
< 
 
β
 
2
 
4–5 Tablet, syrup, dry syrup, inhalant, MDI
Terbutaline
 
β
 
1
 
 
 
< 
 
β
 
2
 
4–6 Tablet, syrup, granule
Third generation
Fenoterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
8 Tablet, syrup, dry syrup, MDI
Procaterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
8–10 Tablet, minitablet, syrup, inhalant, MDI
Tulobuterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
8 Tablet, dry syrup, patch*
Formoterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
10 Tablet, dry syrup, inhalant
Clenbuterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
10–12 Tablet
Salmeterol
 
β
 
1
 
 
 
< < 
 
β
 
2
 
12 Inhalant
 
*Only for Hokunalin
 
®
 
.
MDI, metered dose inhaler.
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Combined effect of salmeterol and an inhaled 
corticosteroid in childhood asthma
 
The effect of salmeterol combined with an inhaled
corticosteroid was examined in a total of 206 moderate
to severe cases.
 
4
 
 Patients currently being treated with
beclomethasone propionate (BDP) or budesonide at a
mean dose of 750 
 
µ
 
g/day were divided into two groups,
one treated with salmeterol inhalant (50 
 
µ
 
g) in combi-
nation twice a day for 12 weeks and the other treated
without the salmeterol inhalant. The time-related
changes (%) in morning peak expiratory flow (PEF) were
monitored in the two groups. The results showed marked
improvement in morning PEF measured at 4 week
intervals (during 1–4 weeks, 5–8 weeks and 9–12 weeks)
in the combined-treatment group compared with the
monotherapy group, suggesting that the morning dip in
the former group was markedly suppressed.
 
4
 
 A meta-
analysis of the results in patients over 12 years of age
showed highly convincing efficacy in patients treated
with combination therapy.
 
5,6
 
 Interestingly, methacholine-
induced airway hypersensitivity was no more severe in
patients treated with salmeterol alone for 4 months than
in patients treated with salbutamol alone.
 
7
 
 However,
controversial findings, such as absence of improvement
of airway hypersensitivity in patients treated with salme-
terol alone but improvement in those treated with BDP
alone, have been reported in patients treated with
salmeterol or BDP alone for 1 year.
 
8
 
 Therefore, the results
cited above do not support treatment with salmeterol
alone on a long-term basis
 
8,9
 
 and, instead, support
therapy with a combination of an LABA and inhaled
corticosteroid. One reason for this is that 
 
β
 
2
 
-adrenergic
receptor agonists prevent the decrease in steroid recep-
tor sensitivity caused by repeated exposure to inhaled
corticosteroids and, because steroids reverse the down-
regulation and reduction in number of 
 
β
 
2
 
-adrenergic
receptors induced by repeated dosing with 
 
β
 
2
 
-adrenergic
receptor agonist,
 
10
 
 corticosteroids and 
 
β
 
2
 
-adrenergic recep-
tor agonists compensate for the shortcomings of each
other.
 
Clinical benefits of salmeterol in exercise-induced 
asthma
 
To assess the effectiveness of salmeterol in suppress-
ing exercise-induced asthma (EIA), salmeterol inha-
lant (50 
 
µ
 
g/day) was administered prophylactically
once to 13 asthmatic patients aged 8–15 years who
had an exercise load-induced FEV
 
1.0
 
 reduction of
> 15%. Exercise loading was performed 1.5 and 9 h
after administration and FEV
 
1.0
 
 was measured 30 min
after loading-indicated reductions. The salmeterol inha-
lant had a prophylactic effect on EIA.
 
11
 
 No differences in
EIA were observed when two salmeterol powder-delivery
devices were used
 
12
 
 and salmeterol inhalation had a
longer-acting prophylactic effect on EIA than the SABA
albuterol.
 
13
 
Safety of salmeterol
 
The safety margin of salmeterol and salbutamol have
already been established in a double-blind study on
childhood asthma comparing the two drugs.
 
14
 
 The inci-
dence of adverse reactions in children in Japan is 2.8%
and one case of palpitations (0.31%) and two cases of
tremors (0.62%) have been documented (Table 2). The
incidence of adverse effects in the cardiovascular and
nervous systems was significantly lower than with oral
 
β
 
2
 
-adrenergic receptor agonists.
 
Ranking of salmeterol according to pediatric 
asthma treatment guidelines
 
Salmeterol inhalant is a useful agent with sufficient
efficacy for the long-term management or control of
childhood asthma in ordinary family life. The Global
Initiative for Asthma (GINA) 2002 Guidelines (Fig. 2)
recommend combined use with an anti-inflammatory
agent, such as inhaled corticosteroid, from step 3
onward.
 
1
 
 In addition, salmeterol has again been recom-
mended for combined therapy with anti-inflammatory
agents, such as inhaled corticosteroids, for 6–15-year-
old asthma patients in Japan according to the 2002
Japanese Pediatric Allergy Guidelines on Childhood
Asthma Management and Treatment.
 
15
Table 2 Comparison of the adverse effects of salmeterol and
the tulobuterol patch giving the incidence of adverse effects in
children after official approval for use in Japan
Item TBP Salmeterol
No. subjects evaluated 401 322
No. with adverse effects 41 9
Incidence adverse effects (%) 10.22 2.80
No. with palpitations (%) 1 (0.25) 1 (0.31)
No. with tremor (%) 0 (0) 2 (0.62%)
No. with throat discomfort (%) – 1 (0.31)
No. with redness at patchsite (%) 21 (5.24) –
TBP, tulobuterol patch.
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Further studies on salmeterol
Airway vascular remodeling in adults is unaffected by
3 month combination therapy consisting of salmeterol
inhalant and an inhaled corticosteroid.16 However,
airway remodeling is induced by the salmeterol inhalant
combined with steroid inhalation in rats.17 Thus, an
investigation of the effect of salmeterol inhalant on
airway remodeling in childhood asthma is needed.
Tulobuterol patch
Special features of TBP
The TBP (Hokunalin-Tape®; Abbott and Maruho
pharmaceutical, Osaka, Japan) exploits the transdermal
absorption model formula to deliver the quantity of drug
required for the time required to attenuate systemic
adverse effects and suppress the morning dip. In short,
systemic adverse effects can be attenuated by preventing
excessive increases in drug concentration coupled with
suppression of the morning dip by administration before
bedtime, because attainment of the peak blood concen-
trations requires an interval of approximately 10 h.18,19
A single administration of TBP each day is sufficient to
provide the daily effects required.
Suppressive effect of TBP on the morning dip
Changes in morning and night-time PEF values have
been measured before and after the administration of
Fig. 2 Drug regimens for the
long-term management of pedi-
atric bronchial asthma (Global
Initiative for Asthma1).
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tulobuterol dry syrup and TBP.20 After 1 week of admin-
istration, both preparations elicited a significant increase
in the morning and night-time PEF values compared
with pretreatment values, but there were similar degrees
of improvement in PEF and no significant differences
between the dosage forms. Based on this finding, the
improvement in pulmonary function in childhood asthma
by TBP administered once daily before bedtime is
equivalent to the effect achieved by two daily oral
doses of dry syrup. Furthermore, a suppressive effect
on morning dip was implied and a concentration-
dependent improvement effect of tulobuterol on PEF was
also shown.21
Combined effects of TBP and inhaled corticosteroid 
in childhood asthma
Changes in the asthma attack scores in seven cases of
severe asthma (mean age 9 years) treated with a combi-
nation of inhaled corticosteroid and TBP for 6 months
showed significant attenuation for the first month,
followed by significant decreases until 6 months of
administration compared with the value 1 month before
the start of therapy; PEF values also increased signifi-
cantly.21 These findings suggest that good efficacy can
be achieved for at least 6 months by combination
therapy consisting of an inhaled corticosteroid and
TBP and that no adverse effects were encountered.
The combined therapy with TBP was effective against
the morning dip in severe childhood asthma, despite the
repeated corticosteroid inhalation regimen.22 The results
strongly suggest that long-term use of TBP is required for
the persistent suppression of the morning dip.
Clinical benefits of TBP in EIA
Five patients with severe asthma (mean age 8 years) who
were subject to EIA were treated with combination
therapy, consisting of an inhaled steroid plus TBP. The
preventive effects on EIA were monitored with a peak
flowmeter before and after combined therapy and the
PEF values were compared. Decreased postexercise PEF
values were reversed and a significantl improvement in
PEF values was observed even at 6 h after exercise
loading. These findings suggest that TBP not only sup-
presses the morning dip in severe asthma, but is also
useful as a prophylactic agent for EIA.22
Safety of TBP
Based on the adverse effects encountered in children
(Table 2), the induction of tremors and palpitations by
TBP was noted at the time of drug approval in Japan,
but the incidence of these side-effects was a significantly
lower than with other oral β2-adrenergic receptor ago-
nists. No tremors have been reported in children and
only one case of palpitations (0.25%) has been docu-
mented.22 However, trivial skin problems, such as itch-
ing, rashes and irritation at patch sites, have been
encountered in 5.2% of cases tested.22
Ranking of TBP according to the pediatric asthma 
treatment guidelines
The TBP is a useful agent for the long-term management
and control of childhood asthma in daily family life. The
TBP has a long-acting bronchodilator effect equivalent to
that of LABA and the 2002 Guidelines for the Treatment
and Management of Childhood Asthma in Japan15
recommend TBP for use in combined therapy with anti-
inflammatory agents, especially inhaled corticosteroid, in
patients of all ages from infancy to adolescence.
Further study on TBP
Studies on drug tolerance and adverse effects, as well as
the effects of TBP on airway hypersensitivity and airway
remodeling over a 1 year period of continuous use, are
Table 3 Comparison of the special features of salmeterol and the tulobuterol patch
Item TBP Salmeterol
Duration of action (h) 24 12
Suppression of morning dip + +
Effectiveness of ICS in combination with + +
Suppressive effect on EIA + +
Appropriate age range (years) 0.5–15 6–15
Drug compliance + (visually apparent) +
Education + (simple) ± (complicated procedure)
TBP, tulobuterol patch; ICS, inhaled corticosteroid; EIA, exercise-induced asthma.
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warranted in children. Multicenter studies have recently
confirmed the absence of adverse effects of a continu-
ous 2 week regimen of TBP and inhaled-steroid com-
bined therapy on airway hypersensitivity23 and TBP can
be used as a reliever for short periods in actual clinical
practice to prevent night-time–morning acute asthma
attacks. When used in this way, the parents must use
TBP to prevent transient attacks based on an individual
assessment. In doing so, the use of TBP may result in
the apparent control of asthma, whereas in reality
airway inflammation may persist, progress or be exac-
erbated. In other words, the use of TBP may lead to
undertreatment by anti-inflammatory agents. Parents of
asthmatic children should be given proper guidance
with thorough complementary explanations on the
correct use of TBP.
CONCLUSIONS
The special features (Table 3) and adverse effects
(Table 2) of salmeterol and TBP, both of which are
agents with a long-acting bronchodilator action, were
compared. The duration of action, appropriate age
range, drug compliance and education differ little from
those of combined therapy with inhaled corticosteroids
in terms of suppressing the morning dip, preventing EIA
and the low incidence of adverse effects on the cardio-
vascular system. Thus, salmeterol and TBP have high
efficacy and an excellent safety margin as broncho-
dilators for the long-term management of childhood
asthma. Furthermore, the special features of the drug
design of these two agents facilitate age-related admin-
istration routes: salmeterol is appropriate for children
more than 6 years of age, whereas TBP is appropriate
for infants more than 6 months of age.
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